dc.contributor.author |
Naiker, Suhashni
|
|
dc.contributor.author |
Connolly, Cathy
|
|
dc.contributor.author |
Wiesner, Lubbe
|
|
dc.contributor.author |
Kellerman, Tracey
|
|
dc.contributor.author |
Reddy, Tarylee
|
|
dc.contributor.author |
Harries, Anthony
|
|
dc.contributor.author |
McIlleron, Helen
|
|
dc.contributor.author |
Lienhardt, Christian
|
|
dc.contributor.author |
Pym, Alexander
|
|
dc.date.accessioned |
2015-07-30T03:59:04Z |
|
dc.date.available |
2015-07-30T03:59:04Z |
|
dc.date.issued |
2014-11-19 |
|
dc.identifier.citation |
Naiker, S., Connolly, C., Wiesner, L., Kellerman, T., Reddy, T., Harries, A., ... & Pym, A. (2014). Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacology and Toxicology, 15(1), 61. |
|
dc.identifier.uri |
http://hdl.handle.net/11427/13604
|
|
dc.identifier.uri |
http://dx.doi.org/10.1186/2050-6511-15-61
|
|
dc.description.abstract |
Abstract
Background
Pharmacokinetic interactions between rifampicin and protease inhibitors (PIs) complicate the management of HIV-associated tuberculosis. Rifabutin is an alternative rifamycin, for patients requiring PIs. Recently some international guidelines have recommended a higher dose of rifabutin (150 mg daily) in combination with boosted lopinavir (LPV/r), than the previous dose of rifabutin (150 mg three times weekly {tiw}). But there are limited pharmacokinetic data evaluating the higher dose of rifabutin in combination with LPV/r. Sub-optimal dosing can lead to acquired rifamycin resistance (ARR). The plasma concentration of 25-O-desacetylrifabutin (d-RBT), the metabolite of rifabutin, increases in the presence of PIs and may lead to toxicity.
Methods and results
Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily. The rifabutin dose with ART was switched after 1 month. Serial rifabutin and d-RBT concentrations were measured after 4 weeks of each treatment. The median AUC0–48 and Cmax of rifabutin in patients taking 150 mg rifabutin tiw was significantly reduced compared to the other treatment arms. Geometric mean ratio (90% CI) for AUC0–48 and Cmax was 0.6 (0.5-0.7) and 0.5 (0.4-0.6) for RBT 150 mg tiw compared with RBT 300 mg and 0.4 (0.4-0.4) and 0.5 (0.5-0.6) for RBT 150 mg tiw compared with 150 mg daily. 86% of patients on the tiw rifabutin arm had an AUC0-24 < 4.5 μg.h/mL, which has previously been associated with acquired rifamycin resistance (ARR). Plasma d-RBT concentrations increased 5-fold with tiw rifabutin dosing and 15-fold with daily doses of rifabutin. Rifabutin was well tolerated at all doses and there were no grade 4 laboratory toxicities. One case of uveitis (grade 4), occurred in a patient taking rifabutin 300 mg daily prior to starting ART, and grade 3 neutropenia (asymptomatic) was reported in 4 patients. These events were not associated with increases in rifabutin or metabolite concentrations.
Conclusions
A daily 150 mg dose of rifabutin in combination with LPV/r safely maintained rifabutin plasma concentrations in line with those shown to prevent ARR.
Trial registration
ClinicalTrials.gov Identifier:
NCT00640887 |
|
dc.rights |
This is an Open Access article distributed under the terms of the Creative Commons Attribution License |
* |
dc.rights.uri |
http://creativecommons.org/licenses/by/2.0 |
* |
dc.source |
BMC Pharmacology and Toxicology |
en_ZA |
dc.source.uri |
http://www.biomedcentral.com/bmcpharmacoltoxicol/
|
|
dc.subject.other |
Rifabutin |
en_ZA |
dc.subject.other |
Pharmacokinetics |
en_ZA |
dc.subject.other |
Lopinavir |
en_ZA |
dc.subject.other |
Tuberculosis |
en_ZA |
dc.subject.other |
HIV |
en_ZA |
dc.subject.other |
DDI |
en_ZA |
dc.subject.other |
Randomized |
en_ZA |
dc.subject.other |
Clinical trial |
en_ZA |
dc.subject.other |
Neutropenia |
en_ZA |
dc.subject.other |
Uveitis |
en_ZA |
dc.title |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy |
|
dc.type |
Journal Article |
en_ZA |
dc.date.updated |
2015-01-15T17:59:11Z |
|
dc.language.rfc3066 |
en |
|
dc.rights.holder |
Naiker et al.; licensee BioMed Central Ltd. |
|
uct.type.publication |
Research |
en_ZA |
uct.type.resource |
Article
|
en_ZA |
dc.publisher.institution |
University of Cape Town |
|
dc.publisher.faculty |
Faculty of Health Sciences |
en_ZA |
dc.publisher.department |
Division of Clinical Pharmacology |
en_ZA |
uct.type.filetype |
|
|
uct.type.filetype |
Text |
|
uct.type.filetype |
Image |
|
dc.identifier.apacitation |
Naiker, S., Connolly, C., Wiesner, L., Kellerman, T., Reddy, T., Harries, A., ... Pym, A. (2014). Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. <i>BMC Pharmacology and Toxicology</i>, http://hdl.handle.net/11427/13604 |
en_ZA |
dc.identifier.chicagocitation |
Naiker, Suhashni, Cathy Connolly, Lubbe Wiesner, Tracey Kellerman, Tarylee Reddy, Anthony Harries, Helen McIlleron, Christian Lienhardt, and Alexander Pym "Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy." <i>BMC Pharmacology and Toxicology</i> (2014) http://hdl.handle.net/11427/13604 |
en_ZA |
dc.identifier.vancouvercitation |
Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, et al. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacology and Toxicology. 2014; http://hdl.handle.net/11427/13604. |
en_ZA |
dc.identifier.ris |
TY - Journal Article
AU - Naiker, Suhashni
AU - Connolly, Cathy
AU - Wiesner, Lubbe
AU - Kellerman, Tracey
AU - Reddy, Tarylee
AU - Harries, Anthony
AU - McIlleron, Helen
AU - Lienhardt, Christian
AU - Pym, Alexander
AB - Abstract
Background
Pharmacokinetic interactions between rifampicin and protease inhibitors (PIs) complicate the management of HIV-associated tuberculosis. Rifabutin is an alternative rifamycin, for patients requiring PIs. Recently some international guidelines have recommended a higher dose of rifabutin (150 mg daily) in combination with boosted lopinavir (LPV/r), than the previous dose of rifabutin (150 mg three times weekly {tiw}). But there are limited pharmacokinetic data evaluating the higher dose of rifabutin in combination with LPV/r. Sub-optimal dosing can lead to acquired rifamycin resistance (ARR). The plasma concentration of 25-O-desacetylrifabutin (d-RBT), the metabolite of rifabutin, increases in the presence of PIs and may lead to toxicity.
Methods and results
Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily. The rifabutin dose with ART was switched after 1 month. Serial rifabutin and d-RBT concentrations were measured after 4 weeks of each treatment. The median AUC0–48 and Cmax of rifabutin in patients taking 150 mg rifabutin tiw was significantly reduced compared to the other treatment arms. Geometric mean ratio (90% CI) for AUC0–48 and Cmax was 0.6 (0.5-0.7) and 0.5 (0.4-0.6) for RBT 150 mg tiw compared with RBT 300 mg and 0.4 (0.4-0.4) and 0.5 (0.5-0.6) for RBT 150 mg tiw compared with 150 mg daily. 86% of patients on the tiw rifabutin arm had an AUC0-24 < 4.5 μg.h/mL, which has previously been associated with acquired rifamycin resistance (ARR). Plasma d-RBT concentrations increased 5-fold with tiw rifabutin dosing and 15-fold with daily doses of rifabutin. Rifabutin was well tolerated at all doses and there were no grade 4 laboratory toxicities. One case of uveitis (grade 4), occurred in a patient taking rifabutin 300 mg daily prior to starting ART, and grade 3 neutropenia (asymptomatic) was reported in 4 patients. These events were not associated with increases in rifabutin or metabolite concentrations.
Conclusions
A daily 150 mg dose of rifabutin in combination with LPV/r safely maintained rifabutin plasma concentrations in line with those shown to prevent ARR.
Trial registration
ClinicalTrials.gov Identifier:
NCT00640887
DA - 2014-11-19
DB - OpenUCT
DO - 10.1186/2050-6511-15-61
DP - University of Cape Town
J1 - BMC Pharmacology and Toxicology
LK - https://open.uct.ac.za
PB - University of Cape Town
PY - 2014
T1 - Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
TI - Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
UR - http://hdl.handle.net/11427/13604
ER -
|
en_ZA |